A body of research extending over three quarters of a century shows that myeloid cells including macrophages are highly dependent on glycolysis for energy metabolism. 1 Subsequently, several lines of evidence have linked macrophage proinflammatory activation with cellular energetics. [2] [3] [4] However, the precise nature of this link remains poorly understood. It was recently shown that hypoxic macrophages upregulate the expression of glucose transporters, hexokinase II, and the ubiquitous form of 6-phosphofructo-2-kinase (encoded by PFKFB3) to substantially increase the glycolytic flux.
A body of research extending over three quarters of a century shows that myeloid cells including macrophages are highly dependent on glycolysis for energy metabolism. 1 Subsequently, several lines of evidence have linked macrophage proinflammatory activation with cellular energetics. [2] [3] [4] However, the precise nature of this link remains poorly understood. It was recently shown that hypoxic macrophages upregulate the expression of glucose transporters, hexokinase II, and the ubiquitous form of 6-phosphofructo-2-kinase (encoded by PFKFB3) to substantially increase the glycolytic flux. 5 However, it remains unknown whether this increased glycolytic flux occurs to simply maintain constant energy delivery in an anerobic environment or it parallels a similar increase in proinflammatory activation. Moreover, the relationship between macrophage proinflammatory activation and energetics is not well understood in the setting of an atherogenic milieu. Accordingly, in this series of investigations, we sought to investigate the relationship between 2 fundamental processes: energy metabolism and inflammatory activation of macrophages in an atherogenic environment.
Inflammation plays an important role in a wide range of diseases. Atherosclerosis is a chronic inflammatory condition accounting for the largest share of mortality in the developed world 6 and is one of the most devastating of inflammatory conditions. Consequently, there is a critical need for greater understanding of the biological mechanisms underlying atherosclerotic inflammation and its complications, including plaque rupture and intraplaque hemorrhage. 7, 8 Atherosclerosis is characterized by macrophage-predominated inflammation existing in the context of proinflammatory cytokines, oxidized low-density lipoproteins (oxLDL), and hypoxia within the arterial wall. [9] [10] [11] [12] Despite mounting evidence that hypoxia promotes inflammation in cancer, obesity, and other inflammatory diseases, 13 in atherosclerosis, the mechanism and precise contribution of hypoxia to other plaque constituents (eg, cytokines and oxLDL) on the proinflammatory milieu remains to be established and a recent study questioned whether proinflammatory stimuli present in atheroma upregulate macrophage glucose metabolism at all. 14 We studied macrophage responses to a range of proinflammatory stimuli relevant to atherosclerosis and observed that proinflammatory stimuli substantially increased both the rate of glycolysis (flux) and proinflammatory activation (eg, tumor necrosis factor [TNF]-α production). Moreover, we found that glycolytic flux and proinflammatory activation show a significant correlation over a range of physiological inflammatory stimuli and across normoxic and hypoxic conditions. We also noted that hypoxia substantially potentiates the effect of cytokines on both glycolytic flux and proinflammatory activation (in similar proportions). We then demonstrated that blocking hypoxia sensing or enzymes responsible for high glycolytic flux substantially reduced both the proinflammatory activation and the glycolytic flux of macrophages. Moreover, inhibition of glycolysis after PFKFB3 expression has a profound effect on murine and human macrophage viability, leading to enhanced necrotic and apoptotic death under proinflammatory conditions. Subsequently, we confirmed the in vivo relevance of our findings in an animal model.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Hypoxia Potentiates Macrophage Proinflammatory Activation and Glycolysis
In atherosclerosis, as with other inflamed tissues, the microenvironment plays a key role in determining the activation state of macrophages. Cytokines are an important constituent of the inflammatory milieu influencing macrophage commitment along a classical (M1 proinflammatory) or alternative (M2 anti-inflammatory) polarization. 15 To establish a firm basis for the series of experiments in this study, we sought to confirm the known effects of various M1 versus M2 activators on elicited peritoneal murine macrophage polarization. In addition, we evaluated the relative action of granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that is relevant to the atheroma and a potent macrophage regulator, 16 which served as a physiological classical stimulus given its ubiquitous, endogenous expression in rodents and humans. [16] [17] [18] [19] [20] [21] [22] Despite the relative importance of GM-CSF to macrophage biology in vivo, the metabolic impact of GM-CSF on macrophage metabolism is not well understood. Accordingly, we examined macrophages after exposure to cytokine (classical stimuli: TNF-α, interleukin [IL]-1β, interferon-γ), lipopolysaccharide (innate stimulus), IL4/IL13 (alternative stimulus), and GM-CSF. Using complementary techniques to evaluate the polarization ( Figure 1A-1D ), we observed as expected that M1 markers increased after classic or innate activation (with lipopolysaccharide and cytokine), whereas M2 markers increased after stimulation with IL4/IL13. Furthermore, we observed that GM-CSF exerts a M1-like polarization, resulting in mild increases in NO and TNF-α accumulation, ( Figure 1B and 1C) , well-accepted signatures of the M1 activation. [23] [24] [25] Furthermore, under either classic or innate stimuli, we observed a shift in the gene expression of the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), from the liver type-PFK2 (PFKFB1), which has a low net kinase activity, to the more active inducible form PFKFB3 ( Figure 1D ). This response was further exacerbated under hypoxic conditions, as suggested by the increased hypoxia-inducible factor (HIF)-1α levels ( Figure 1E and 1F) . It is well established that PFKFB3 has greater kinase than bisphosphatase activity 26 and thus favors the rise in fructose-2,6-bisphosphate (Fru-2,6-P 2 ), a potent regulator of upper glycolysis that is required for high glycolytic rates. 5, 26, 27 
Observations Under Atherogenic Conditions
Next, we evaluated the actions of key atherosclerotic constituents (oxLDL, LDL, and hypoxia) 7, 28 on murine macrophage proinflammatory activation and glycolysis. We found that oxLDL and GM-CSF (but not LDL) each resulted in proinflammatory activation of murine macrophages (Figure 2A) . Notably, hypoxia on its own did not increase proinflammatory stimulation. However, in cells exposed to GM-CSF or oxLDL, hypoxia substantially potentiated proinflammatory activation (Figure 2A, right) . The effects on glycolysis of these atherosclerotic constituents were similar to those on TNF-α production: oxLDL, GM-CSF, and cytokine each resulted in substantial increases in Fru-2,6-P 2 concentration ( Figure 2B ). Moreover, although hypoxia alone caused a minimal increase in glycolysis, hypoxia markedly potentiated the glycolytic flux in the presence of proatherogenic mediators (cytokines and oxLDL; Figure 2B , right; Figure 2C ). Furthermore, while hypoxia alone was not associated with an increase in glucose consumption in nonactivated macrophages, hypoxia substantially potentiated the effect of cytokine and GM-CSF ( Figure 2D ). These results agree with the expression levels of genes encoding the glucose transporter Glut-1 and the genes encoding hexokinase II and PFKFB3, the enzyme responsible for the high-throughput synthesis of Fru-2,6-P 2 . We observed a similar action of hypoxia on the expression of those genes: hypoxia had a minor impact on its own, but substantially potentiated the actions of cytokine and GM-CSF ( Figure 2E ).
Close Inter-Relationship Between Glycolysis and Proinflammatory Activation. Role of TNF-α
Because we observed that both macrophage proinflammatory activation and energetics increase in the presence of atherosclerotic mediators, we sought to define the strength of the inter-relationship between these 2 processes. We observed a strong linear correlation (R=0.97; P<0.001) between glycolytic flux (as Fru-2,6-P 2 levels) and proinflammatory activity (measured as TNF-α production) under both hypoxic and normoxic conditions ( Figure 3A) . Hence, we demonstrate that macrophage glycolysis keeps pace with the proinflammatory activated state of the cell regardless of oxygen tension. Moreover, because GM-CSF promotes TNF-α synthesis, we sought to determine its contribution to the glycolytic phenotype. As Figure 3B shows, the presence of neutralizing antibodies against TNF-α in the culture medium significantly attenuated the expression of PFKFB3, the rise in Fru-2,6-P 2 levels and the release of lactate, providing a link for TNF-α between the inflammatory and glycolytic profiles.
PFKFB3 Regulates Both Glycolytic Metabolism and Inflammation
Given the strong linear association between macrophage glycolysis and inflammatory activity in murine cells, we next sought to evaluate whether (1) a high glycolytic rate was necessary for inflammatory activation and (2) this relationship was maintained in human macrophages. To investigate this, human macrophages were separately treated with 2 inhibitors of PFKFB3: (1) a human small interfering RNA targeting PFKFB3 and (2) (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) (3PO), a selective inhibitor of PFKFB3. 29 In the first experiment, we observed that silencing PFKFB3 effectively attenuated PFKFB3 without affecting the constitutively expressed PFKFB1 or hexokinase II ( Figure 4A ), and thus did not affect basal glycolysis ( Figure 4B ). However, we observed that inhibition of PFKFB3 activity under stimulatory conditions results in a significant reduction in glycolytic flux (measured as Fru-2,6-P 2 levels and lactate release; Figure 4B and Figure IA and IB in the online-only Data Supplement, respectively). In parallel to these findings, we found that blocking PFKFB3 resulted in a significant reduction in proinflammatory activation (measured by TNF-α production; Figure 4C ) across oxygen tensions and under a range of stimuli. Thereafter, we tested the hypothesis that high-flux glycolysis is required to maintain macrophage viability under conditions of proinflammatory stimulation. In this experiment, we observed that blocking PFKFB3 did not reduce the viability of resting macrophages; however, under conditions of proinflammatory stimulation, the viability of activated macrophages decreased when PFKFB3 was inhibited ( Figure 4D ). Taken together, these observations provide evidence that the ability to upregulate PFKFB3 activity is necessary to maintain the viability of activated (but not resting) macrophages.
HIF-1α Also Regulates Both Glycolytic Metabolism and Inflammation
Because we observed that hypoxia potentiates macrophage proinflammatory activation, we hypothesized that interruption of hypoxia-sensing might attenuate inflammation in an atherosclerotic environment. Indeed, within the context of cancer, it has recently been shown that hypoxia-induced overexpression of HIF-1α results in metabolic adaptation (a shift to glycolysis from Krebs cycle and oxidative phosphorylation) which in turn facilitates cell survival. 30 We sought to evaluate whether a similar relationship exists in atherosclerotic macrophages. We observed that silencing HIF-1α substantially reduced glycolytic flux (as Fru-2,6-P 2 levels and lactate; Figure 5A and 5B) across oxygen tensions and under various proinflammatory conditions. In parallel, blocking HIF-1α substantially reduced proinflammatory activation of macrophages (as TNF-α production; Figure 5C ). Furthermore, we observed that inhibition of either PFKFB3 or HIF-1α resulted in proportionate reductions in both glycolysis (as Fru-2,6-P 2 ) and proinflammatory activation (R=0.68, P=0.007; Figure 5D ). In addition to this, we evaluated the role of hypoxia on the inducibility of PFKFB3 in response to GM-CSF. As Figure 5E shows, macrophages transfected with a plasmid carrying the HRE sequence of the human pfkfb3 promoter (29 nucleotides, from −1297 to −1269) linked to a luciferase reporter [31] [32] [33] exhibited an increase not only in activity because of hypoxia but also by the action of GM-CSF, a response that was enhanced under hypoxic conditions. Collectively, these observations suggest that both upregulation of upper glycolysis and proinflammatory activation are dependent on HIF-1α across oxygen tensions, highlighting the cross talk between hypoxic and nonhypoxic signaling pathways in the regulation of metabolic adaptation in response to atherosclerotic stimuli. Indeed, silencing of HIF-1α provoked a loss in viability with increased rates of apoptosis and necrosis compared to controls ( Figure 5F ). This was especially evident in the presence of oxLDL or under hypoxic conditions. This finding reaffirms that an intact HIF-1α system is required for macrophage survival in an atherosclerotic microenvironment and that survival of activated macrophages is also dependent on high glycolytic flux, through upregulation of PFKFB3. In addition to this, O 2 consumption decreased in M1 macrophages. Moreover, under Figure 3 . Close inter-relationship between murine macrophage proinflammatory activation (TNF-α) and Fru-2,6-P 2 concentration as indicator of glycolysis. A, Correlation between the accumulation of TNF-α in the culture medium and intracellular Fru-2,6-P 2 concentrations under the experimental conditions described in Figures 1 and 2 . B, Neutralizing goat antimouse TNF-α Abs (10 μg/mL) in the culture medium prevent 6-phosphofructo-2-kinase (PFKFB3) induction, the rise in Fru-2,6-P 2 concentration and the release of lactate in macrophages treated for 24 hours with granulocyte-macrophage colony-stimulating factor (GM-CSF; 20 ng/mL) under normoxic and hypoxic (1% O 2 ) conditions. Goat IgG (10 μg/mL) was used as control immunoglobulin. Results show a representative blot and the mean+SD of three experiments. **P<0.01 vs the same IgG condition. low glucose availability, forcing respiration with FCCP (carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) resulted in cell death of M1 cells, but not in resting or M2 counterparts ( Figure 6A ). Moreover, GM-CSF depressed mitochondrial ATP synthesis ( Figure 6B ), but enhanced nonmitochondrial O 2 consumption in agreement with ROS production, in particular, in the presence of oxLDL ( Figure 6C and 6D) .
Inhibition of PFKFB3 and HIF-1α Attenuates Glycolytic Flux in ApoE −/− Mice
We then sought to evaluate the impact of selective inhibition of PFKFB3 and HIF-1α on glycolytic flux in atherosclerotic mice (ApoE −/− mice fed a high-fat diet). Glycolysis in the arterial wall was assessed using 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomogrphic imaging before and after impairing PFKFB3 (using 3PO or PFKFB3 small interfering RNA) and HIF-1α (using HIF-1α small interfering RNA). Subsequently, we removed the arterial segments and measured tissue levels of PFKFB3, Fru-2,6-P 2 , TNF-α, and C-C motif chemokine 2 (CCL2). We observed substantial attenuation of glycolysis (measured as a target:background ratio of FDG uptake) after inhibition of either PFKFB3 or HIF-1α ( Figure 7A ). Moreover, and HIF-1α), and inhibition of PFKFB3 (3PO; 10 μmol/L). E, After transfection of macrophages with a luciferase reporter plasmid containing the HRE domain of the pfkfb3 promoter, or the mutated sequence lacking HRE binding (pHREwt. Luc and pHREmut.Luc, respectively, at 600 ng/mL each) and a β-galactosidase plasmid (60 ng/mL) cells were submitted for 4 hours to normoxia or hypoxia (1% O 2 ) and then activated for 6 hours with GM-CSF. The ratio between the luciferase and β-galactosidase activities was determined for in the same cell extracts. F, After activation for 60 hours with GM-CSF or CK, the percentage of apoptotic/necrotic cells was determined. Results show the mean+SD (n=3; A, B, and D) or a representative experiment out of 3 (C). *P<0.05; **P<0.01 vs the same condition with scRNA (A and B) , vs the basal condition under normoxia (E) or vs the corresponding LDL condition (F). #P<0.05; ##P<0.01 vs the same condition under normoxia (A and B).
after removal of the arterial tissues, we measured the tissue quantities of PFKFB3 and Fru-2,6-P 2 and found that their tissue levels mirrored the measurements of FDG uptake across the tested conditions ( Figure 7B and 7C) . Similarly, the tissue measurements of proinflammatory mediators TNF-α and CCL2 were similarly affected by the inhibitors (Figure 7D ). Also, silencing or inhibition of PFKFB3 resulted in an enhancement of active caspase 3 in the plaque (Figure 7E ), confirming the loss in cell viability under these conditions. Interestingly, all animals were alive and stable after treatment courses. Given the tenacious relationship between glycolysis and inflammation, these in vivo observations raise the possibility that antagonism of HIF-1α or modulation of glycolysis may provide a pharmacological approach to alleviate the inflammatory burden in atherosclerotic disease.
Discussion
The findings of this study highlight the basis for and importance of macrophage metabolic adaptation within atherosclerosis. We show that hypoxia potentiates macrophage glycolytic flux along with a proportional upregulation of proinflammatory activity (in a manner that is dependent on both HIF-1α and PFKFB3). Moreover, we show that antagonizing either HIF-1α or PFKFB3 activities simultaneously impairs both glycolysis and proinflammatory activation in vitro, and we provide translational evidence of this phenomenon in vivo. Furthermore, we show that impairing either HIF-1α or PFKFB3 in the setting of proinflammatory stimulation results in loss of monocyte viability after activation of caspase cascades. The potential impact of reduced monocyte/macrophage viability in atherosclerotic plaques is unclear. Macrophage proliferation within plaque has been described, 34 and reduced viability of such cells, as well perhaps of other macrophages, may indeed be beneficial. However, there is also the possibility of detrimental effects of enhancing cell death with possible postapoptotic necrosis if efferocytosis is deficient. Thus, additional work is needed to better understand the implications of such modulation of macrophage viability within the atheroma.
The observation that hypoxia increases glycolysis is a phenomenon referred to, in cancer cells, as the Warburg Effect 35 and appears to be involved in macrophage physiology at different points of their maturation and function. 36 One proposed explanation for Warburg observation is that hypoxia obligates a shift in metabolism, from the tricarboxylic acid cycle to glycolysis simply to compensate for loss of aerobic metabolism. 37 However, our observations provide an alternate explanation for the Warburg Effect, at least as far as it relates to atherosclerotic macrophages, namely that (1) hypoxia also increases the proinflammatory activation of macrophages and (2) the glycolytic rate is increased in a manner that keeps pace with this increased inflammatory and proatherogenic activity, namely because of the contribution of oxLDL to the enhanced glucose consumption and ROS production. 10, 11 Collectively, these observations give rise to a paradigm wherein hypoxia can act to exacerbate a cycle of inflammation ( Figure 8 ). Within this paradigm, cytokines trigger upregulation of HIF-1α, which is stabilized under hypoxic conditions. 38, 39 HIF-1α, after transcriptional induction of PFKFB3 leads to increased proinflammatory activation and increased glycolysis. 5, 29, 32, 33, 40, 41 The activated macrophages then produce additional cytokines to perpetuate this vicious inflammatory cycle.
Our data have potentially important implications for the treatment of atherosclerotic inflammation. We found that selective inhibition (or silencing) of PFKFB3, HIF-1α, or both results in a substantial reduction in proinflammatory activation. Along these lines, PFKFB3 has been recently shown to play a regulatory role in proliferation 34, 41 and angiogenesis. 40 Accordingly, drugs that target PFKFB3 or hypoxia sensing, which are also currently in development as cancer therapeutics, [42] [43] [44] [45] should be further studied in the context of atherosclerosis. Moreover, studies should assess whether targeting PFKFB3 or reducing hypoxia sensing within plaques will decrease atherosclerotic inflammation and its clinical consequences. Indeed, in a previous work using macrophages deficient for HIF-1α in the myeloid lineage, 5 we were surprised by the observation that glycolysis remained increased and PFKFB3 was also overexpressed, perhaps because of the fact that HIF-2α assumed part of the transcriptional control caused by HIF-1α. 46 Therefore, the rationale for the use of PFKFB3 inhibitors offers many advantages because this enzyme is only expressed under hypoxic and proinflammatory conditions.
The study findings also have important implications for imaging of atherosclerosis. Although the bulk of previous evidence suggests that proinflammatory stimulation is associated with increased glycolysis, 1 recent study suggested that hypoxia and not proinflammatory activation augments macrophage glucose metabolism.
14 That report proposed that imaging measures of glucose metabolism (eg, with labeled 2-deoxyglucose) may provide an indirectly assessment tissue hypoxia in vivo.
14 However, the findings of the current study suggest that measures of glycolysis are not well suited for assessing hypoxia. Specifically, we observe, across oxygen tensions, that glycolytic flux remains tightly related to the state of macrophage proinflammatory activity, (eg, TNF-α production; Figure 3) , thus supporting the use of FDG to image inflammatory cell activity within atheromatous plaques. On the contrary, we found that oxygen tension per se is not a good predictor of the degree of inflammation because proinflammatory activity varies markedly within both normoxic and hypoxic conditions, depending on the availability of other proinflammatory factors, such as oxLDL and cytokines (Figure 2A) . Accordingly, hypoxia-directed probes (such as FMISO [ 18 F-fluoromisonidazole]), while likely colocalize to sites of inflammation, may not be so useful for reporting on the level of proinflammatory activation that exists in those lesions.
The central importance of inflammation to atherosclerosis warrants pursuit of a deeper understanding of the interconnection between hypoxia, glycolysis, and inflammatory activation within an atheroma. This study demonstrates that a surprisingly tight interconnection exists between macrophage glycolysis and proinflammatory activity, that the link requires HIF-1α and transcriptional induction of PFKFB3, and that inhibition of either under proinflammatory conditions results in a reduction in inflammatory activity. Hence, modulation of macrophage metabolic adaptation may provide an opportunity to develop novel treatments against atherosclerotic inflammation. Figure 8 . Hypoxia potentiates macrophage proinflammatory activation, thereby strengthening a vicious cycle. A, Cytokines trigger upregulation of hypoxia-inducible factor (HIF)-1α, which is further stabilized by hypoxic conditions. HIF, after binding to the promoter region of 6-phosphofructo-2-kinase (PFKFB3) leads to increased glycolysis and to increased proinflammatory activation and maintained viability. The viable activated macrophages then produce additional cytokines to perpetuate this vicious inflammatory cycle. Antagonism of HIF-1α or PFKFB3 results in decreased proinflammatory activation and metabolism and reduced viability.
